CN Patent

CN110022878A — Egfr/pi3k的小分子双重抑制剂及其用途

Assigned to University of Michigan System · Expires 2019-07-16 · 7y expired

What this patent protects

本发明属于药物化学领域。具体而言，本发明涉及一类新的具有喹唑啉结构、起到EGFR和PI3K双重抑制剂作用的小分子，及其用作用于治疗癌症(例如，与突变的KRAS和BRAF相关的癌症)的治疗剂(例如，与MAPK途径抑制剂(例如，BRAF抑制剂、MEK抑制剂、ERK抑制剂)组合)的用途。

USPTO Abstract

本发明属于药物化学领域。具体而言，本发明涉及一类新的具有喹唑啉结构、起到EGFR和PI3K双重抑制剂作用的小分子，及其用作用于治疗癌症(例如，与突变的KRAS和BRAF相关的癌症)的治疗剂(例如，与MAPK途径抑制剂(例如，BRAF抑制剂、MEK抑制剂、ERK抑制剂)组合)的用途。

Drugs covered by this patent

dabrafenib-mesylate (DABRAFENIB MESYLATE)

Patent Metadata

Patent number: CN110022878A
Jurisdiction: CN
Classification: —
Expires: 2019-07-16
Drug substance claim: No
Drug product claim: No
Assignee: University of Michigan System
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.